Table 3.
Seroconversion rates (≥ fourfold increase) in baseline seronegative participants in each group at each time-point, n/N (%)
| Placebo | 2 μg | 4 μg | 6 μg | 8 μg | 12 μg | |
|---|---|---|---|---|---|---|
| S protein IgG | ||||||
| Day 8 |
0/22 (0) |
0/36 (0) |
1/37 (3) |
0/34 (0) |
1/32 (3) |
0/23 (0) |
| Day 29 |
0/22 (0) |
2/36 (6) |
6/37 (16) |
6/37 (16) |
9/35 (26) |
4/23 (17) |
| Day 43 |
0/20 (0) |
27/34 (79) |
27/34 (79) |
25/36 (69) |
27/34 (79) |
19/20 (95) |
| RBD IgG | ||||||
| Day 8 |
0/22 (0) |
0/35 (0) |
0/37 (0) |
0/34 (0) |
1/32 (3) |
0/23 (0) |
| Day 29 |
0/22 (0) |
0/36 (0) |
1/35 (3) |
1/37 (3) |
0/35 (0) |
1/23 (4) |
| Day 43 |
0/20 (0) |
13/34 (38) |
27/34 (79) |
25/36 (69) |
28/34 (82) |
21/23 (91) |
| S protein or RBD IgG | ||||||
| Day 8 |
0/22 (0) |
0/35 (0) |
1/37 (3) |
0/34 (0) |
2/32 (6) |
0/23 (0) |
| Day 29 |
0/22 (0) |
2/36 (6) |
7/36 (19) |
1/37 (19) |
9/35 (26) |
5/23 (22) |
| Day 43 |
0/20 (0) |
27/34 (79) |
31/34 (91) |
30/36 (83) |
32/34 (94) |
23/23 (100) |
| Virus neutralizing titers | ||||||
| Day 8 |
0/22 (0) |
0/38 (0) |
0/37 (0) |
0/34 (0) |
0/32 (0) |
0/23 (0) |
| Day 29 |
0/22 (0) |
0/36 (0) |
1/37 (3) |
0/37 (0) |
5/35 (14) |
0/23 (0) |
| Day 43 |
2/20 (10) |
24/34 (71) |
23/34 (68) |
20/36 (56) |
27/34 (79) |
19/23 (83) |
Italicised numbers are percentages